Department of Pediatrics, Children's National Hospital and George Washington University School of Medicine and Health Sciences, Washington, DC.
Department of Pediatrics, Children's National Hospital and George Washington University School of Medicine and Health Sciences, Washington, DC.
Ann Allergy Asthma Immunol. 2022 Aug;129(2):194-198.e1. doi: 10.1016/j.anai.2022.03.033. Epub 2022 Apr 8.
Pediatric asthma exacerbations account for substantial morbidity, including emergency department (ED) visits and hospitalizations. Although the coronavirus disease 2019 (COVID-19) pandemic was associated with a decrease in pediatric asthma ED visits and hospitalizations, there is limited information on the clinical characteristics of children hospitalized with an asthma exacerbation during the pandemic.
To investigate the clinical characteristics of children hospitalized with an asthma exacerbation during the pandemic as compared with those hospitalized during the same months in the year prior.
A retrospective case-control study was conducted at the Children's National Hospital, Washington, DC, comparing demographic and clinical characteristics of all children, 2 to 18 years old, hospitalized for an asthma exacerbation between April to September 2020 (cases) and April to September 2019 (controls).
We identified 50 cases and 243 controls. Cases were significantly older than controls (9.8 ± 4.3 years vs 6.7 ± 3.8 years; P < .001), had significantly less eczema (16% vs 32.1%; P = .02) and food allergies (6% vs 18.5%; P = .03), and were more noncompliant with controller medications (46% vs 24.7%; P = .002) than controls. Magnesium sulfate was more frequently administered in the ED to the cases than to the controls (84% vs 63%; P = .004). Its use was associated with older age, African American race, and Hispanic ethnicity, but was independent of comorbid conditions.
Patients hospitalized for asthma during the COVID-19 pandemic were older and have less atopy than those hospitalized prepandemic. A larger proportion received magnesium sulfate in the ED, suggesting patients had with more severe asthma presentation during the pandemic.
儿科哮喘发作会导致大量发病，包括急诊就诊和住院。尽管 2019 年冠状病毒病（COVID-19）大流行与儿科哮喘急诊就诊和住院人数减少有关，但有关大流行期间因哮喘加重而住院的儿童的临床特征的信息有限。
与前一年同期相比，调查大流行期间因哮喘加重而住院的儿童的临床特征。
在华盛顿特区儿童国家医院进行了一项回顾性病例对照研究，比较了 2020 年 4 月至 9 月（病例）和 2019 年 4 月至 9 月（对照组）期间所有因哮喘加重而住院的 2 至 18 岁儿童的人口统计学和临床特征。
我们确定了 50 例病例和 243 例对照。病例组明显比对照组年龄大（9.8 ± 4.3 岁比 6.7 ± 3.8 岁；P <.001），湿疹（16%比 32.1%；P =.02）和食物过敏（6%比 18.5%；P =.03）明显较少，且不遵守控制器药物的比例明显更高（46%比 24.7%；P =.002）。与对照组相比，镁硫酸盐在急诊室更频繁地用于病例组（84%比 63%；P =.004）。它的使用与年龄较大，非裔美国人种族和西班牙裔有关，但与合并症无关。
与大流行前相比，COVID-19 大流行期间因哮喘住院的患者年龄较大，且过敏症较少。ED 中使用更大比例的硫酸镁，表明大流行期间患者的哮喘表现更为严重。
